If I have to sit through one more presentation titled "The Future of Care Delivery" that offers zero insight into actual margins or operational hurdles, I am walking out. In my eleven years of building conference portfolios for mid-size biotechs and top-15 pharma teams, I have seen millions of dollars wasted on "presence" at conferences that do nothing but serve stale coffee and buzzwords.
You are likely facing the biggest infrastructure dilemma of your career: ambulatory infusion. Do you build your own specialty pharmacy and site-of-care network, or do you partner with health systems to offload the headache? This isn't a branding exercise; it is a balance sheet decision. To make that choice, you need to stop collecting business cards and start collecting data. Here is how you map your conference calendar to the reality of the build versus partner debate.
The Build vs. Partner Framework: Defining the Goal
Before you book a flight, define the outcome. Are you trying to secure a distribution channel, or are you trying to understand if a hospital network will even allow your drug on their formulary?
Building gives you control. You own the patient journey, the data, and the speed of initiation. But you also own the compliance risk, the overhead, and the battle for reimbursement. Partnering with health systems shifts that burden, but it forces you into the slow, opaque world of health system operations, where your drug becomes one of thousands fighting for a preferred status.
The Comparison Matrix
Metric In-House Build Health System Partner Speed to Market Slow (Operational ramp-up) Fast (Leverages existing infrastructure) Control High (Patient journey ownership) Low (Lost to hospital processes) Margin Impact High CAPEX, Variable OPEX Compressed due to administrative fees Access Barrier Compliance/Credentialing Formulary approval/P&T CommitteesConference Selection: Outcomes Over Hype
I keep a "Do Not Attend" list. If a conference is marketed as a "Must-Attend Event" and uses buzzwords like "paradigm shift" or "synergy" without showing a single operational case study, it is a waste of your travel budget. Here is how I structure a strategic year around the events that actually force a decision.
1. BIO Partnering: The Summer Anchor
If you are exploring the build versus partner spectrum, you are likely looking at whether you need to license a network or integrate with a platform. BIO Partnering is your anchor for the summer because it is transactional. You aren't there to listen to panels; you are there to find the distribution partners or service providers who can handle the heavy lifting of infusion services.
Why it works: The platform allows for high-level filtering. If you go in with the goal of "finding a partner," you will fail. If you go in with the goal of "vetting three companies capable of managing complex site-of-care infusion for rare disease," you will get results. It moves the discussion from abstract strategy to specific licensing or service-level agreements.
2. Fierce Pharma Week: Commercial Execution & CI
Once you’ve decided on your lane, you need to know what your competition is doing. Fierce Pharma Week is excellent for competitive intelligence (CI). In the world of ambulatory infusion, your competitors aren't just other drugs; they are other models. Are your rivals successfully building in-house hubs? Are they locking down exclusive partnerships with major hospital networks?
Use this event to pressure-test your strategy. Look for the tracks focusing on commercial execution. If you see your competitors shifting from wholesale to direct-to-site distribution, your ambulatory infusion model needs to adapt immediately. Do not use this time for networking—use it for interrogating the speakers on the "how," not the "why."
3. The Health Management Academy (THMA): The Reality Check
If you want to understand health system operations, you have to talk to the people who manage the P&T committees. The Health Management Academy (THMA) is one of the few places where pharma can sit across from C-suite leaders of major health systems. This is where you find out if your "value proposition" is actually getting through the noise.
You will learn the reality of formulary adoption here. You’ll hear them complain about the administrative burden of your infusion requirements. You’ll hear them explain why they prefer one partner over another. This is the "no-nonsense" zone. If you leave this event without a concrete understanding of why a hospital system would choose your ambulatory strategy over their own internal processes, you haven't done your job.
Avoiding the "Conference Trap"
The most common mistake I see among commercial leads is the belief that being "present" at a conference increases brand equity. It doesn't. If you aren't walking away with a list of actionable changes for your ambulatory infusion model, you are losing money on travel and opportunity costs.
Checklist: Before you book, ask these three questions
Is the audience the decision-maker or the marketer? If the room is full of vendors selling to other vendors, do not go. Is there a concrete case study? If the agenda is vague, email the organizers and ask for the specific learning outcomes. If they can’t provide them, the conference is a fluff-fest. Can I influence my "Build vs. Partner" strategy with the data I gain here? If the answer is "no," cancel the trip and put the budget toward internal data analysis or a targeted consultant.The Reality of Health System Adoption
When you are debating ambulatory infusion, you are ultimately fighting for shelf space in a world that is moving toward site-of-care optimization. Health systems are obsessed with managing costs and reducing length-of-stay. If your infusion model doesn't align with their efficiency metrics, they won't care how "innovative" your drug is.
At THMA forums, I often hear pharma teams pitch their drug’s clinical efficacy, while the health system leaders are asking about the complexity of the infusion, the storage requirements, and the reimbursement coding. If you are building an in-house model, you need to ensure your backend supports the billing and coding realities that worldpharmatoday.com health systems prioritize. If you are partnering, your contract must account for the fact that the health system will prioritize the drugs that are easiest to administer and most profitable to manage.
Conclusion: Stop Attending, Start Executing
The build versus partner conversation shouldn't happen at a cocktail hour. It should happen in your boardroom, supported by the cold, hard intelligence you gathered from focused events like BIO and THMA. Stop treating your event budget as a "marketing expense" and start treating it as a "strategic intelligence investment."
The next time you look at your calendar, don’t look for the event with the biggest stage or the most "industry experts." Look for the event that forces you to confront the operational friction of your ambulatory infusion strategy. If it makes you uncomfortable, that’s how you know it’s worth the travel.